Travere Therapeutics (TVTX) Liabilities and Shareholders Equity (2011 - 2026)

Travere Therapeutics' Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $555.2 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 1.16% year-over-year to $555.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 2.54% YoY) and the FY2025 annual result came in at $605.2 million, up 1.86% from the prior year.
• Liabilities and Shareholders Equity was $555.2 million for Q1 2026 at Travere Therapeutics, down from $605.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $832.8 million in Q3 2023 and bottomed at $504.4 million in Q3 2024.
• A 5-year average of $664.1 million and a median of $663.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity increased 17.3% — and 2024, when it plunged 39.44%.
• Travere Therapeutics' Liabilities and Shareholders Equity stood at $672.6 million in 2022, then rose by 17.3% to $788.9 million in 2023, then decreased by 24.69% to $594.1 million in 2024, then gained by 1.86% to $605.2 million in 2025, then fell by 8.26% to $555.2 million in 2026.
• Business Quant data shows TVTX's Liabilities and Shareholders Equity at $555.2 million in Q1 2026, $605.2 million in Q4 2025, and $538.6 million in Q3 2025.